• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解帕金森病的哪些方面对患者和家属最重要。

Understanding what aspects of Parkinson's disease matter most to patients and families.

机构信息

College of Nursing & Health Sciences, University of Massachusetts Dartmouth, Dartmouth, Massachusetts, USA.

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

出版信息

Sci Rep. 2024 Sep 11;14(1):21171. doi: 10.1038/s41598-024-71555-4.

DOI:10.1038/s41598-024-71555-4
PMID:39256441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11387791/
Abstract

Understanding what matters to people with Parkinson's and their family is essential to derive relevant clinical outcome measures and guide clinical care. The purpose of this study was to explore what is important to people with Parkinson's disease vs. family over time. A qualitative content-analysis of online survey data collected by Parkinson's UK was conducted to identify types and frequencies of important symptoms and impacts of Parkinson's for people with the disease vs. family of people with Parkinson's. Independent T-tests were used to identify significance of between group differences for patients vs. family at < 2, 2-5, 6-10, 11-20, > 20-year durations. ANOVA was used to assess for within group differences by disease duration. We found that symptom priority changed significantly over time with longer disease duration. Tremor was reported less often later on, whereas mobility, dyskinesias, gait and speech/communication symptoms gained priority. In general, patients identified movement-related symptoms (e.g., walking, bradykinesia) as the most bothersome at all durations while family more strongly prioritized the physical and psychosocial impacts of disease (e.g., mobility, safety, interpersonal interactions, independence, and family impact). We conclude that important differences exist between family and patient perspectives of what matters and change over time with longer duration of disease.

摘要

了解帕金森病患者及其家属关心的问题对于得出相关的临床结果测量指标和指导临床护理至关重要。本研究旨在探讨随着时间的推移,帕金森病患者和患者家属关注的重要问题有何不同。通过对帕金森英国(Parkinson's UK)在线调查数据进行定性内容分析,以确定帕金森病患者和患者家属各自认为的重要症状类型和频率,以及帕金森病对他们的影响。采用独立样本 T 检验,比较患者与患者家属在疾病持续时间<2 年、2-5 年、6-10 年、11-20 年、>20 年时的组间差异显著性。采用方差分析,评估不同疾病持续时间的组内差异。我们发现,随着疾病持续时间的延长,症状的优先顺序发生了显著变化。震颤在后期出现的频率较低,而运动、运动障碍、步态和言语/交流症状的优先级上升。总的来说,患者在所有疾病持续时间内都认为与运动相关的症状(如行走、运动迟缓)最令人困扰,而家属则更强烈地关注疾病的身体和心理社会影响(如行动能力、安全性、人际互动、独立性和家庭影响)。我们的研究结果表明,患者和家属对重要问题的看法存在显著差异,并且随着疾病持续时间的延长而发生变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d5/11387791/75262bf0eb2c/41598_2024_71555_Fig2a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d5/11387791/b9e226b2c379/41598_2024_71555_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d5/11387791/75262bf0eb2c/41598_2024_71555_Fig2a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d5/11387791/b9e226b2c379/41598_2024_71555_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d5/11387791/75262bf0eb2c/41598_2024_71555_Fig2a_HTML.jpg

相似文献

1
Understanding what aspects of Parkinson's disease matter most to patients and families.了解帕金森病的哪些方面对患者和家属最重要。
Sci Rep. 2024 Sep 11;14(1):21171. doi: 10.1038/s41598-024-71555-4.
2
Impacts of gait freeze on quality of life in Parkinson's disease, from the perspectives of patients and their carers.从患者及其照料者的角度看步态冻结对帕金森病患者生活质量的影响。
Ir J Med Sci. 2024 Aug;193(4):2041-2050. doi: 10.1007/s11845-024-03673-x. Epub 2024 Apr 19.
3
"It's a disease of families": Neurologists' insights on how to improve communication and quality of life for families of Parkinson's disease patients.“这是一种家族性疾病”:神经科医生的见解——如何改善帕金森病患者家庭的沟通和生活质量。
Chronic Illn. 2020 Sep;16(3):201-211. doi: 10.1177/1742395318799852. Epub 2018 Sep 12.
4
People with Parkinson's Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?帕金森病患者:他们最希望改善哪些症状,以及随着疾病持续时间的变化,这种情况会如何变化?
J Parkinsons Dis. 2021;11(2):715-724. doi: 10.3233/JPD-202346.
5
Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.早期帕金森病患者的体验:运用混合方法分析确定哪些概念对临床试验结果评估至关重要。
Neurol Ther. 2022 Sep;11(3):1319-1340. doi: 10.1007/s40120-022-00375-3. Epub 2022 Jul 1.
6
Experience and Impact of OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners.帕金森病“OFF”期的体验和影响:对医生、患者和护理人员的调查。
J Parkinsons Dis. 2020;10(1):315-324. doi: 10.3233/JPD-191785.
7
Palliative care for Parkinson's disease: Patient and carer's perspectives explored through qualitative interview.帕金森病的姑息治疗:通过定性访谈探索患者及照料者的观点
Palliat Med. 2017 Jul;31(7):634-641. doi: 10.1177/0269216316669922. Epub 2016 Sep 28.
8
Symptom progression in advanced Parkinson's disease: Dyadic perspectives.晚期帕金森病的症状进展:对偶视角。
Appl Nurs Res. 2019 Dec;50:151193. doi: 10.1016/j.apnr.2019.151193. Epub 2019 Sep 4.
9
Caregiver burden in Parkinson's disease: a mixed-methods study.帕金森病患者照料者负担:一项混合方法研究。
BMC Med. 2023 Jul 10;21(1):247. doi: 10.1186/s12916-023-02933-4.
10
Clinical effects of robot-assisted gait training and treadmill training for Parkinson's disease. A randomized controlled trial.机器人辅助步态训练和 treadmill 训练对帕金森病的临床效果。一项随机对照试验。
Ann Phys Rehabil Med. 2019 Sep;62(5):303-312. doi: 10.1016/j.rehab.2019.06.016. Epub 2019 Aug 1.

引用本文的文献

1
Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson's Disease.用于评估帕金森病疾病进展和治疗效果的PARCOMS综合量表的开发与验证
Neurol Ther. 2025 Aug;14(4):1609-1625. doi: 10.1007/s40120-025-00771-5. Epub 2025 Jun 16.
2
Examining the lived experience of dementia with Lewy bodies through qualitative research: A systematic review.通过定性研究审视路易体痴呆的生活经历:一项系统综述。
Alzheimers Dement. 2025 May;21(5):e70217. doi: 10.1002/alz.70217.
3
Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease.

本文引用的文献

1
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义:建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
2
Patient With Parkinson Disease and Care Partner Perceptions of Key Domains Affecting Health-Related Quality of Life: Systematic Review.帕金森病患者及其照护者对影响健康相关生活质量的关键领域的认知:系统评价。
Neurology. 2024 Feb 13;102(3):e208028. doi: 10.1212/WNL.0000000000208028. Epub 2024 Jan 12.
3
Caregiver burden in Parkinson's disease: a mixed-methods study.
帕金森病早期有意义症状及功能影响的系统评价与共识概念模型
NPJ Parkinsons Dis. 2025 Apr 3;11(1):65. doi: 10.1038/s41531-025-00907-2.
4
Investigation of the voice handicaps in Parkinson's disease and determination of the clinical correlates.帕金森病语音障碍的调查及临床相关性的确定。
J Neural Transm (Vienna). 2025 Jun;132(6):859-866. doi: 10.1007/s00702-025-02910-6. Epub 2025 Mar 24.
帕金森病患者照料者负担:一项混合方法研究。
BMC Med. 2023 Jul 10;21(1):247. doi: 10.1186/s12916-023-02933-4.
4
What Patients Say: Large-Scale Analyses of Replies to the Parkinson's Disease Patient Report of Problems (PD-PROP).患者说:帕金森病患者报告问题(PD-PROP)的大规模分析回复。
J Parkinsons Dis. 2023;13(5):757-767. doi: 10.3233/JPD-225083.
5
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.帕金森病临床试验药物治疗:2023 年更新。
J Parkinsons Dis. 2023;13(4):427-439. doi: 10.3233/JPD-239901.
6
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's Disease.将数字测量与早期帕金森病中的有意义症状和影响相关联。
J Parkinsons Dis. 2023;13(4):589-607. doi: 10.3233/JPD-225122.
7
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease.早期帕金森病患者症状的相对意义和影响。
J Parkinsons Dis. 2023;13(4):619-632. doi: 10.3233/JPD-225068.
8
An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.对美国食品药品监督管理局就《以患者为中心的药物研发指南3:选择、开发或修改适用的临床结局评估》草案的访谈
Value Health. 2023 Jun;26(6):791-795. doi: 10.1016/j.jval.2023.04.006. Epub 2023 Apr 26.
9
Perspectives of people with Parkinson's disease and family carers about disease management in community settings: A cross-country qualitative study.帕金森病患者及其家庭照顾者对社区环境中疾病管理的看法:一项跨国定性研究。
J Clin Nurs. 2023 Aug;32(15-16):5201-5218. doi: 10.1111/jocn.16636. Epub 2023 Feb 2.
10
The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations.二元认知报告和主观认知衰退在早期ADRD临床研究与试验中的作用:当前认知、差距及建议
Alzheimers Dement (N Y). 2022 Oct 4;8(1):e12357. doi: 10.1002/trc2.12357. eCollection 2022.